Covaxin approves for 12 to 18 years age groupZYDUSLIFE - 357 Change: 18.10 (5.34 %)
News: DCGI has granted emergency use authorisation to Bharat Biotech’s Covaxin in the paediatric age group between 12 and 18 years. It is the second vaccine after Cadila’s ZyCoV-D to have received approval in the paediatric age group. According to media sources, ZyCov-D will not be part of initial paediatric vaccination (15-18 years) from January 3.
Views: Cadila has received EUA for ZyCov-D in August, 2021 with a rollout expected by September end but ZyCov-D is yet to see a full rollout. However with the overhang of Omicron, DCGI’s approval for Covaxin and national vaccination programme for paediatric age group (15-18 years), it is more likely to see the estimated ZyCov-D contribution to pan out. We remain watchful of official rollout and vaccination programme and had factored in this new competition (SEC recommended Covaxin in October, 2021) for NPV of ~ Rs.30 per share for ZyCoV-D in our estimates.